rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

SAB Biotherapeutics, Inc.

SABS · Nasdaq

Health CareBiotechnologyNot moving yet

SABS stood above a rising 150-day average in 33 of the last 52 weekly readings, and has been out of that trend for the last 15 weeks. It is 28.1% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 15
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
85 (+13)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 33 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders85+13 on the quarter
New · exited32 · 20
Reported value$267.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Caligan Partners LPunchanged · filed 14 Aug 20267,967,207$31.1M00.0%
Vivo Capital, LLCreduced · filed 14 Aug 20267,299,909$28.5M-4,120,091−36.1%
PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 20266,627,501$25.8M+195,758+3.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.added · filed 14 Aug 20266,405,553$25.0M+3,000,000+88.1%
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 20264,401,500$17.2M00.0%
Balyasny Asset Management L.P.unchanged · filed 14 Aug 20263,760,439$14.7M00.0%
BlackRock, Inc.added · filed 7 Aug 20263,066,016$12.0M+2,764,690+917.5%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,972,929$11.6M+479,192+19.2%
Commodore Capital LPreduced · filed 14 Aug 20262,870,000$11.2M-1,531,500−34.8%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 20262,749,087$10.7M-283,610−9.4%
31 Dec 2023 – 30 Jun 2026
64482Dec 23Sep 24Mar 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Alexandra Kropotova Company insiderCHIEF MEDICAL OFFICER · last 17 Sep 20260 · 0
Christoph Lawrence Bausch Company insiderCHIEF OPERATING OFFICER · last 3 Feb 20260 · 0
Eddie Joe Sullivan Company insiderPRESIDENT · last 3 Feb 20262 · 0
Lucy To Company insiderOfficer · last 3 Feb 20260 · 0
Samuel J. Reich Company insiderCEO · last 3 Feb 20263 · 0
David Zaccardelli Company insiderDirector · last 5 Jan 20260 · 0
Rita Jain Company insiderDirector · last 5 Jan 20260 · 0
David Link Company insiderDirector · last 16 Dec 20250 · 0
Erick Lucera Company insiderDirector · last 16 Dec 20250 · 0
Helen K. Ellias Company insiderDirector · last 16 Dec 20250 · 0
Jay S. Skyler Company insiderDirector · last 16 Dec 20250 · 0
Scott Giberson Company insiderDirector · last 16 Dec 20250 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-30.2%
Cash conversionFY 2025 · to 31 Dec 2025-337%
Share count trendFY 2025 · to 2 Mar 20267.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$10.5M
Free cash flowFY 2025 · to 31 Dec 2025−$45.7M

Analyst forecasts

No analyst forecasts yet.